This Month
- Exclusive
- Funding
New fund targets companies battered by market doubts
Record low biotech valuations have prompted a new VC investor to start shopping with a planned $200 million fund.
- Jessica Sier
Soul Patts-backed IPO hopeful Nicolab back in front of investors
The Amsterdam-based medtech is back on the fund-raising trail just seven months after its last cash call.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Mesoblast taps Bell Potter for $98m equity raising
The biotech company launched its latest raising on Friday morning to fund clinical trials.
- Sarah Thompson, Kanika Sood and Emma Rapaport
October
The key to this biotech’s tilt at US fortune is pure pigs
A Perth-based regenerative medicine company is preparing for a major expansion into the US market with a unique “collagen velcro” sourced from Australian pigs that repairs severed nerves.
- Tom Rabe
Drug repurposing biz Paradigm Biopharma preps raise; taps Bell Potter
The company, founded in 2014 by former CEO Paul Rennie, is hoping to commercialise a new treatment for knee osteoarthritis.
- Sarah Thompson, Kanika Sood and Emma Rapaport
How CSL’s new CEO stacks up against Brian McNamee and Paul Perreault
Less than a year into the job leading the blood products giant, Paul McKenzie is already under pressure to continue the company’s great Australian success story,
- Patrick Durkin
Anteris Technologies raising $40m; Evolution Cap on ticket
The company was offering shares at $20 apiece, which was a tight 3 per cent discount to Anteris’s last close, for a minimum $40 million raise.
- Sarah Thompson, Kanika Sood and Emma Rapaport
- Opinion
- Sharemarket
Obesity drug sell-offs based on ‘guess work’
The quandary of equity valuation is demonstrated by the sell-off of CSL and ResMed on a yet-to-be-proven assertion about obesity drugs.
- Giselle Roux
- Opinion
- Shares
What’s been eating CSL? Blue chip company feels the Ozempic effect
One of Australia’s most loved businesses has come under attack from two powerful macro forces. It must now convince investors it’s the same old CSL.
- Jonathan Shapiro
- Opinion
- Science
Another scandal dogs a science cheat
Celebrity culture in research can lead to an escalation of exaggerated claims.
- F.D. Flam
Next Gardasil should be manufactured here, says vaccine inventor
The immunologist responsible for the HPV cervical cancer vaccine says Australia still lacks the facilities to manufacture the next medical breakthrough locally.
- Tess Bennett
September
CSL cracks the genetic code of haemophilia B treatment
When CSL launched its innovative haemophilia B treatment Hemgenix, patients cried.
- Yolanda Redrup
Melbourne life sciences biz in strategic review; hires Rothschild
The business, which has seen strong growth since its founding five years ago, has called up the Rothschild bankers.
- Sarah Thompson, Kanika Sood and Emma Rapaport
August
Gary Paykel-backed NZ biotech launches capital raise; Ords on ticket
Auckland BioSciences is in the market seeking to raise $9.2 million from high net-worth-investors.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Billionaire-backed Next Science raising $29m
Next Science, owner of medical solutions to prevent surgical and wound infections, launched a $28.9 million raising on Tuesday morning split across five legs.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Carlyle goes all in on biotech Opthea; MST launches $80m capital raise
The private equity giant has signalled its intention to take up an option to invest another $80 million in the clinical-stage biotech
- Sarah Thompson, Kanika Sood and Emma Rapaport
Beyond patents: How to turn research into social impact
This company is hunting for programmers to recast medical imaging and disease detection in the same way that Uber and Airbnb have transformed ride sharing and tourism.
- Agnes King
Imugene in $60m cash call for new licensing deal; Bells on ticket
The money will be used to fund the acquisition of a licence for Precision Biosciences’ azer-cel allogeneic cancer treatment.
- Sarah Thompson, Kanika Sood and Emma Rapaport
- Updated
- Earnings season
CSL sheds pandemic chains as it chases plasma boost
Underlying net profit after tax and amortisation at constant currencies was up 20 per cent, showing a strong rebound from pandemic troubles.
- Updated
- Ben Potter
- Opinion
- Chanticleer
CSL won’t panic as it solves its profit problem
Margins in its key plasma business are under pressure, but new chief Paul McKenzie plans to fix the issue by thinking like a retailer, as well as a scientist.
- James Thomson
